I look forward to seeing how the newer larger biotech funds do/seeing more recent data during a time where public tech outperformed rest of public market.
I'd be careful reading too much into data on top performing funds. The law of large numbers makes it so that smaller funds are more likey to outperform (and underperform) since they have higher variance. Couple that with the strong correlation that speciality funds are more likely to be smaller and it's not surprising.
A more accurate analysis would involve looking at all VCs and seeing if you can apply those rules in advance:
What would your IRR be if you invested in all the specialty biotech funds as a basket?
I look forward to seeing how the newer larger biotech funds do/seeing more recent data during a time where public tech outperformed rest of public market.